Education
About Us
Working with TipRanks
Follow Us
Helix BioPharma (TSE:HBP)
TSX:HBP
HBP Stock Chart & Stats
C$2.32
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.32
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.65 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$152.02M
Enterprise ValueC$50.20M
Total Cash (Recent Filing)C$65.00K
Total Debt (Recent Filing)C$335.00K
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding74,155,760
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.65 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$152.02M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Mar 18, 2026 which is in 95 days.
How were Helix BioPharma’s earnings last quarter?
Currently, no data Available
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 74,155,760 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
Company Description
Helix BioPharma
Helix BioPharma Corp. is a biotechnology company focused on the development of innovative drug products for the treatment of cancer. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary technology platforms to develop novel therapies. Helix BioPharma's core product is its lead drug candidate, L-DOS47, which is designed to treat certain types of lung cancer and other solid tumors. The company is dedicated to advancing its clinical programs and expanding its therapeutic portfolio to address unmet medical needs in oncology.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---